A Phase 2 study of acimtamig (AFM13) in patients with CD30-positive, relapsed or refractory peripheral T-cell lymphomas.
Kim WS, Shortt J, Zinzani PL, Mikhailova N, Radeski D, Ribrag V, Domingo Domenech E, Sawas A, Alexis K, Emig M, Elbadri R, Hajela P, Ravenstijn P, Pinto S, Garcia L, Overesch A, Pietzko K, Horwitz S.
Kim WS, et al. Among authors: pinto s.
Clin Cancer Res. 2024 Nov 12. doi: 10.1158/1078-0432.CCR-24-1913. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39531538